Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Acute Myelogenous Leukemia in Childhood
The results of treatment for childhood acute myelogenous leukemia (AML) have improved considerably during the last ten years. This progress was demonstrated by the two consecutive multicenter studies, AML-BFM-78 and -83, in which almost identical extended multi drug regimes of che motherapy were administered for eight weeks and followed up by two years maintenance. The main difference in the second study was the addition of an eight-day intensive in duction course. Due to this new element, the relapse rate was reduced significantly. Another result of the BFM-83 study was the definition of two risk groups on the basis of standardized treatment, which has lead to a risk-adapted treatment strat...
A History of Haematology
A beautifully illustrated account of the remarkable developments within haematology, this insightful volume details the scientists and pioneers central to these advances.
Acute Leukemias II
Acute leukemia a quite homogenous disease failed to break through the sound barriere of when untreated reveals a substantial hetero unsatisfactory cure rates even in special sub geneity in its response to therapy. While cure groups. While new protocols including more is achieved in a certain proportion of pa effective supportive care show some increase tients other cases prove to be highly resis in the initial response rates and certain im tant. The curability is superior in acute provements in the long-term results, no ben lymphoblastic (ALL) than in acute myeloid eficial effect on the relapse rate during the (AML) leukemia and - within both type- first 1 Y2 years emerged from any of these higher in children as compared to adults. regimens. Thus, high chances for cure are The two age groups and cell types can be presently restricted to children with ALL further subdivided into prognostic groups and to lesser proportions children with by special diagnostic features. Thus, in AML and adults with ALL and AML.
Hodgkin’s Disease in Children
Where do you begin to look for a recent, authoritative article on the diagnosis or management of particular malignancy? The few general oncol ogy textbooks are generally out of date. Single papers in specialized journals are informative but seldom comprehensive; these are more often prelimin ary reports on a very limited number of patients. Certain general journals frequently publish good in-depth reviews of cancer topics, and published symposium lectures are often the best overviews available. Unfortunately, these reviews and supplements appear sporadically, and the reader can never be sure when a topic of special interest will be covered. Cancer Treatment and Research is a series of author...
Current Catalog
First multi-year cumulation covers six years: 1965-70.
Ein Meilenstein in der Medizin
Die Verbesserungen der Therapieergebnisse bei der Behandlung der akuten lymphoblastischen Leukämie (ALL) und bei den Non-Hodgkin-Lymphomen (NHL) im Kindesalter stellen in der Medizin etwas Besonderes dar. Von gnadenloser Hoffnungslosigkeit über kurzfristige Therapieerfolge ist die Heilungsrate bei der ALL auf etwa 80% gestiegen. Bei den NHL ist das Ergebnis sogar noch besser. Dieses Buch zeichnet den Weg dieser Geschichte nach. Es beschreibt wie sich die pädiatrische Onkologie in Deutschland organisierte und wie Therapieoptimierungsstudien zum zentralen Element dieser Erfolgsgeschichte wurden. Alle Personen, die mit ihrem Mut und ihrer Entschlossenheit maßgeblich dazu beigetragen h...
Acute Myelogenous Leukemia
The inclusion of experimental and clinical data in a single volume, together with an emphasis on recent and controversial issues, combine to make this treatise unique in its approach to acute myelogenous leukemia (AML). Investigators from diverse disciplines critically examine what is now understood about the pathogenesis of this disease and discuss new and emerging therapeutic approaches. Chapters cover subjects ranging from leukemia in atomic bomb survivors to RAS gene mutations in AML and the pharmacologically directed design of AML therapy.
Acute Leukemias VI
For 10 years the book series Acute Leukemias has been providing updates on the rapid progress being made internationally concerning this group of diseases. The fifth volume mainly addressed experimental approaches, but the present issue presents both therapeutic and prognostic aspects of the most recent results from major multicenter clinical trials. Additional chapters report new trends in leukemia cell biology,the monitoring of minimal residual disease, and secondary leukemias, as well as new antileukemic drugs, antimicrobial strategies, and the use of cytokines. The combined efforts against acute leukemias described in this book explain the recent improvements in the outcome of patients suffering from acute leukemias.
